Zynerba Pharmaceuticals Short Interest Ratio and Short Volume

Short interest is the volume of Zynerba Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of March 31st, investors have sold 2,510,000 shares of ZYNE short.

Zynerba Pharmaceuticals saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 2,510,000 shares, a decrease of 23.7% from the previous total of 3,290,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.00% of Zynerba Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Zynerba Pharmaceuticals: Kadmon Holdings, Inc. (0.00%), Gossamer Bio, Inc. (19.79%), Albireo Pharma, Inc. (0.00%), Evelo Biosciences, Inc. (12.22%), Clovis Oncology (0.00%), OrganiGram Holdings Inc. (6.64%), AnaptysBio, Inc. (16.09%), IDEAYA Biosciences, Inc. (0.00%), Rigel Pharmaceuticals, Inc. (0.00%), and Relmada Therapeutics, Inc. (5.29%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Analog Devices, Inc. ($5.84 billion), Aon plc ($5.47 billion), Charter Communications, Inc. ($5.36 billion), ViacomCBS Inc. ($3.99 billion), Snap Inc. ($3.77 billion), Airbnb, Inc. ($2.90 billion), Peloton Interactive, Inc. ($2.43 billion), Discovery, Inc. ($2.38 billion), The Kroger Co. ($2.28 billion), and Expedia Group, Inc. ($2.18 billion). View all of the most shorted stocks.

Short selling ZYNE is an investing strategy that aims to generate trading profit from Zynerba Pharmaceuticals as its price is falling. Zynerba Pharmaceuticals' stock is trading down $0.09 today. To short Zynerba Pharmaceuticals stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Zynerba Pharmaceuticals will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Zynerba Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ZYNE, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ZYNE, twice per month. The most recent reporting period available is March, 31 2021.